Novo Nordisk Says Global Payer Pressure Limits Price Rises
This article was originally published in The Pink Sheet Daily
Recent SWITCH-2 data encourage plans for submitting supplemental indication of reduced hypoglycemia for Tresiba, company suggests; Victoza sales continue growth but below predictions, and "we are losing market to Trulicity."
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.